# 1. Financial Performance ## A. Key Figures * Revenue (Q2 FY26): **₹430.8 Cr** (+34% YoY) · **H1 FY26 Revenue:** **₹964 Cr** (+14% YoY) * **Gross Margin:** **21%** in Q2 FY26 (+500 bps) · **20%** in H1 FY26 (+500 bps) * EBITDA: Loss of ₹4.4 Cr in Q2 FY26 (vs. ₹31.5 Cr loss) · Profit of ₹2.1 Cr in H1 FY26 (vs. ₹41 Cr loss) ## B. Revenue Growth * **Strong Recovery Momentum:** Revenue growth reflects a rebound in core operations, driven by strategic shift toward higher-margin **bio-based specialty chemicals** and improved market conditions. * **Segmental Strength:** Chemical business delivered **~8% revenue growth** and **45–50% EBITDA growth** in H1, underscoring successful portfolio optimization. * **Catalyst from Policy:** Restoration of the **Ethanol Blending Program** has positively impacted demand and pricing visibility. ## C. Gross Margin * **Significant Margin Expansion:** Gross margin surged due to **favorable product mix**, with higher contribution from specialty bio-chemicals, signaling structural improvement in profitability. ## D. EBITDA Trends * **Path to Profitability:** EBITDA turned positive in H1, reflecting strong operating leverage, cost optimization, and reduced finance costs from debt reduction. ## E. Balance Sheet * **One-Time Exceptional Item:** Retrospective provisioning for labor contracts in **Maharashtra** added one-time cost; management confirms no further impact expected in current/future quarters. --- # 2. Product & Segment Performance ## A. Key Figures * **Bio-Based Chemicals Revenue Growth:** **23%** YoY * **Bio-Based Chemicals EBITDA Growth:** **60%** YoY * **Specialty Chemicals Mix:** **63%** of chemical portfolio (+600 bps) * **Jivana Brand Revenue:** **₹108 Cr** FY25 (₹65 Cr H1) * Ethanol EBITDA: **₹4.7 Cr** in Q2 (vs. ₹2.9 Cr loss YoY) ## B. Bio-Based Chemicals * **Strategic Shift Driving Profitability:** Strong double-digit revenue and EBITDA growth fueled by a meaningful increase in the share of **bio-based specialty chemicals**, now representing a **majority two-thirds mix** of the portfolio. * **Sustainable Growth Trajectory:** Management is structurally committed to expanding the specialty chemicals share further, underpinning long-term margin enhancement and reduced seasonality via **multi-feedstock ethanol investments**. * **Resilient Segment Outlook:** Despite geopolitical volatility affecting individual molecule economics, the biochemicals business delivered robust performance across diverse geographies and applications, with sustained optimism for structural growth. ## C. Ethanol Business * **Volume-Driven Revenue Surge, Limited Margin Flow-Through:** Ethanol revenue scaled sharply QoQ, but EBITDA expansion was minimal despite improved blending economics and off-take, constrained by **transfer pricing dynamics** between sugar and distillery divisions. * **Production & Inventory Tailwinds:** Current strength partly attributable to high prior-year molasses inventory; B-heavy molasses remains the primary feedstock, with ongoing interest in comparative sugar-ethanol seasonality outlook. ## D. Jivana Brand Sales * **Brand Strategy Delivering Scale and Resilience:** Jivana brand has achieved **tripling of revenue** in recent years, reaching ₹108 Cr in FY25, with over 60% booked in H1, demonstrating strong market acceptance and pricing power in volatile conditions. --- # 3. Feedstock & Supply Mix ## A. Key Figures * **Ethanol Allocation:** **289 Cr L** sugar-based (28% of total) · **760 Cr L** grain-based (2025–2026 supply year) ## B. Grain-Based Ethanol * **Government Preference Confirmed:** Clear policy tilt toward grain-based ethanol, with over **70% of total allocation** sourced from grain, signaling long-term strategic direction. ## C. Multi-Feedstock Strategy * **Strategic Flexibility Achieved:** Feedstock diversification into maize and rice enhances resilience against climate, policy, and supply risks, aligning with global market dynamics. * **Capacity Expansion Underway:** Increased allocations to maize-based distilleries validate plans to commission a new grain-based facility, reinforcing a robust multi-feedstock footprint. --- # 4. Capacity & Production ## A. Key Figures * **Ethanol Capacity:** **200-kilo** unit on track for commissioning ## B. Ethanol Plant Ramp-Up * **Seasonal Production Cycle:** Ethanol output follows the sugarcane-ethanol season, spanning Q3 to Q2 of the following fiscal year. * **Favorable Crop Conditions:** Strong monsoons over two years have boosted sugarcane yield and quality across key states, supporting expectations of **higher recovery rates and improved production** this season. ## C. De-Bottlenecking Efforts * **Operational Efficiency Push:** Focus on deep de-bottlenecking of chemical plants to unlock capacity and enhance throughput. ## D. Biobutanol Engineering * **New-Capex Project:** Biobutanol development requires fresh investment; engineering phase ongoing with customer commitments under review for feasibility. --- # 5. R&D & Innovation ## A. Anti-Cancer Trials * **Headline:** Cancer drug advances to preliminary efficacy trial stage following successful Phase I safety completion. * **Headline:** Strategic out-licensing path confirmed; U.S.-facing subsidiary to accelerate partner engagement post-efficacy data. * **Headline:** Goal to identify out-licensing partner within **2–3 years**, significantly shortening time to value versus full commercialization. * **Headline:** Anti-cancer project remains capital-light, with no material impact expected on **₹325 Cr FY29 capex plan**. ## B. DME from CO2 * **Headline:** Pilot-scale CO₂-to-DME project launched with ICT Mumbai, advancing circular carbon and de-fossilization strategy. * **Headline:** DME positioned as clean-burning alternative to **LPG and diesel**, with potential for direct blending into existing fuel infrastructure. * **Headline:** Technology leverages CO₂ emissions from ethanol and power operations as feedstock, creating value from waste streams. ## C. Pilot Projects * **Headline:** CO₂-to-DME initiative has transitioned from lab to pilot phase, with scale-up contingent on results. * **Headline:** Global licensing of DME technology under consideration, reflecting ambition for broad commercial impact. ## D. Drug Discovery Pipeline * **Headline:** Robust oncology pipeline supported by strong internal research team, signaling sustained innovation beyond lead candidate. --- # 6. Policy & Market Risks ## A. Key Figures * Ethanol Diversion: 3.4 million tons (FY25–26, flat YoY) * **Ethanol Production Capacity:** **>1,700 Cr Liters** vs. **1,050 Cr Liters** tendered by OMCs * Sugar Export Approval: 1.5 Mn Ton for 2025–26 (vs. 2 Mn Ton requested) * Projected Sugar Availability: 36 Mn Ton vs. 28.5 Mn Ton domestic demand ## B. Ethanol Pricing * **Pricing Pressure:** Countervailing risk persists from **lack of ethanol price revisions** for sugarcane juice and B-heavy routes, despite capacity outpacing off-take. * **Policy Ahead of Target:** 20% blending achieved five years early, but surplus supply necessitates long-term solutions like **flex-fuel vehicle adoption** and infrastructure for >20% blending. * **Awaited Reforms:** Ethanol price hikes and sugar MSP adjustments remain pending, with no confirmed government timeline. ## C. Sugar Export Rules * **Positive Export Outlook:** Government approval of **15 Cr Ton** sugar exports and **removal of 50% molasses export duty** to ease inventory overhang and support trade competitiveness. * **Market Balancing:** Measures expected to **lighten national sugar stocks** and foster future price stability amid above-average production outlook. ## D. Feedstock Competition * **Cost Concerns Addressed:** Management dismisses rising feedstock costs as a **one-off expense**, not a structural trend, despite competitive pressures. --- # 7. Guidance & Outlook ## A. EBITDA Target * **Path to Profitability:** Management targets EBITDA positivity by end-FY26, driven by de-bottlenecking, expansion in high-value bio-based specialties, multi-feedstock ethanol capacity, and R&D intensification. * **Conditional Commitment:** EBITDA turnaround remains contingent on execution and external factors; no firm guarantee provided. ## B. Revenue Trajectory * **No Near-Term Guidance:** Due to uncertainties in global and domestic conditions—especially export policies—company is withholding specific revenue guidance for FY26. * **Medium-Term Growth View:** Despite near-term caution, management expects **revenue and EBITDA growth** over the next two to three years as new capacities ramp. ## C. Tender Dependence * **Production vs. Sales Timing:** 200 KLPD plant to begin production in Q4 FY26 with **6 crore liters** annual capacity, but sales realization in FY27 hinges on OMC tender awards. * **Tender Risk & Revenue Potential:** First-year sales could reach **INR 400 Cr** if tenders are secured, particularly those expected around September for H2 of FY; outcomes remain uncertain.